The mental healthcare system is in desperate need of innovation.

By combining the growing potential of MDMA with digital therapeutics we aim to deliver safe, scalable psychotherapy to all those who need it — wherever and whenever they need it.

An atai Life Sciences company

EmpathBio is a biotech company dedicated to developing 3,4-Methylenedioxymethamphetamine derivatives in conjunction with digital therapeutics to deliver efficient, scalable treatments to patients on their own terms.

While MDMA-assisted psychotherapy holds great promise for the treatment of PTSD, refinement of MDMA's entactogenic pharmacology could provide for a greater therapeutic index. We want to ensure that entactogen-assisted psychotherapy is available to all struggling with PTSD.

- Glenn Short

, CEO, EmpathBio

Our Team

The EmpathBio Team

Glenn
Short, Ph.D.

SVP, EARLY DEVELOPMENT

Srinivas Rao,
M.D., Ph.D.

Co-founder & Chief Scientific Officer

Florian
Brand

Co-founder & Chief Executive Officer

News

Contact

We'd love to hear from you.

Better mental healthcare is possible. Contact us to learn more about our mission and work.

[email protected]

Follow us on socials







    This site is protected by reCAPTCHA and the Google
    Privacy Policy and
    Terms of Service apply.

    JOIN THE ATAI #INSIGHTNETWORK

    Want to learn more?
    Sign up for weekly updates.

    Email
    submit